No black box warning on record for Arynta

As of the latest FDA labeling reviewed, Arynta (LISDEXAMFETAMINE DIMESYLATE ORAL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Arynta medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Risks to Patients with Serious Cardiac Disease : Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease ( 5.2 ) • Increased Blood Pressure and Heart Rate : Monitor blood pressure and pulse. ( 5.3 ) • Psychiatric Adverse Reactions : Prior to initiating ARYNT

No black box warning on record for Arynta

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Risks to Patients with Serious Cardiac Disease : Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease ( 5.2 ) • Increased Blood Pressure and Heart Rate : Monitor blood pressure and pulse. ( 5.3 ) • Psychiatric Adverse Reactions : Prior to initiating ARYNT

Arynta Black Box Warning

No black box warning on record for Arynta

Other warnings & precautions

Arynta Black Box Warning

No black box warning on record for Arynta

Other warnings & precautions